In line with this, Douguet and coworkers showed that the activation of P2X7 can inhibit the growth of NSCLCs in mice receiving an anti-PD-1 therapy and therefore renders the tumor cells sensitive to this therapy [57]. This evidence concerns the gene PDCD1 and neoplasm.